GLP-1 (glucagon-like peptide) medications, such as Ozempic and Wegovy, have seen a surge in popularity over the past few ...

Altimmune Inc. (NASDAQ: ALT) is a clinical-stage biotechnology company specializing in treating liver disease and obesity.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...

Colonic air insufflation averaged 30 bulb compressions. Thirty-three patients received IV glucagon (1 mg), and 27 patients did not. The colon was divided into eight segments, and the adequacy of ...

Eli Lilly launched its weight loss drug Mounjaro in India. According to the company, the injection is supposed to be taken ...

There is initial evidence that low-dose semaglutide may reduce craving and drinking outcomes in individuals with alcohol-use disorder.

Glucagon-like peptide-1 (GLP-1) receptor agonists ... “CagriSema is an investigational fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and semaglutide 2.4 mg. Novo ...

Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic ... will be available as a 1-count or 10-count package of 1 mg per 0.2 mL single-dose vials.